AzTrials
AzTrials

Takotsubo CardiomyopathySYMPATAKNCT04695587

The Role of Sympathetic Tone Regarding the Anatomical and Functional Recovery of the Left Ventricle in TakoTsubo Syndrome

An observational study of Takotsubo Cardiomyopathy, run by Hippocration General Hospital at 1 site in Greece.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

TakoTsubo Syndrome (TTS) constitutes an increasingly recognised, heterogenous clinical entity which is associated with considerable short-term mortality. In addition, emerging evidence suggests that, in the long term, TTS can induce the expression of a phenotype similar to HFpEF . Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Takotsubo Cardiomyopathy
What is being tested?
123 MIBG scintigraphy testing, MSNA and ABPM
How many people
30 participants
Where
1 siteGreece
Study dates
8 Oct 2019to 7 Oct 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • Adult, Older adult

Study population: This is a prospective, non-interventional observational study which will enroll patients 18-85-year-old, who fulfil the InterTAK diagnostic criteria. The diagnosis will be confirmed with CMR and ECHO which will show the LV systolic recovery. Signed consent form will be obtained and cases that the symptoms were attributed to myocarditis or subendocardial infarction will be excluded. Patients with severe chronic kidney disease (eGFR < 30 ml/min), severe valvular disease, contraindication to perform any of the aforementioned measurements, chronic atrial fibrillation, permanent pacing, autonomic failure, pregnant or breastfeeding women, psychiatric disease which does not allow adequate co-operation or patients with life expectancy less than a year will not be enrolled. The enrolled cases will be followed up for one year. Data will be collected in a specific form (CRF). These include demographic and somatometric data, past medical history, hemodynamics and sympathetic tone measurements.

Who may be able to join

  • age limits
  • Subjects able to provide ICF
  • Cases fullfilling the InterTAK criteria with CMR to exclude acute myocarditis or myocardial infarction

Who cannot join

  • age limits
  • eGFR < 30ml/min
  • Cases diagnosed with acute myocarditis or acute myocardial infarction
  • Severe valvular disease not related to TakoTsubo syndrome
  • Pacemaker dependent patients
  • Contraindications for CMR performance
Show all 13Show fewer
  • Permanent atrial fibrillation
  • Neurological conditions related with autonomic failure
  • Pregnancy, lactation
  • Iodine allergy
  • Chronic heart failure with LVEF < 35%
  • Any condition related with reduced life expectancy at recruitement
  • Cancer on active treatment

Trial locations and contacts

1 site in 1 country.

Konstantinos P Tsioufis, Professor contact

21320880000 ext. 8099

ktsioufis@hippocratio.gr

Ioannis Leontsinis, MD contact

00306937171268

giannisleontsinis@gmail.com

Greece1 site, 1 recruiting
  • First Cardiology Clinic, Hippocration General Hospital, National and Kapodistrian University of Athens, Athens, Greece

    Athens, 11527

    Konstantinos P Tsioufis, Professor, 2132088000 ext. 8099, ktsioufis@hippocratio.gr

    Ioannis E Leontsinis, MD, 6937171268 ext. +30, giannisleontsinis@gmail.com

    Recruiting

Other trials in Greece

About this study

TakoTsubo Syndrome (TTS) constitutes an increasingly recognised, heterogenous clinical entity which is associated with considerable short-term mortality. In addition, emerging evidence suggests that, in the long term, TTS can induce the expression of a phenotype similar to HFpEF . Apart from the typical (apical left ventricular) type, the current TTS definition has been expanded to also include the mid-ventricular, the basal and the focal type. Several previous studies on the typical form of the syndrome demonstrated that the principal underlying pathophysiology is sympathetic overactivation.

Purpose The aim of this study is to investigate the potential association between the sympathetic tone and the acute phase clinical features of TTS. Furthermore, the investigators aim at exploring possible correlations between the sympathetic tone activity and the diastolic dysfunction, a reported complication occurring one year after the acute phase.

Read more

This is a prospective observational study enrolling patients aged 18-85 years who fulfill the InterTaK diagnostic criteria and whose CMR within 14 days of the onset is not suggestive of an alternative diagnosis. All patients will be treated on individual basis according to the recent expert consensus statement for TTS. During the baseline evaluation the sympathetic tone will be assessed by means of Muscle Sympathetic Nerve Activity study (MSNA), heart rate and blood pressure variability parameters. Additionally, in a subgroup of participants sympathetic activity and cardiac sympathetic enervation will be evaluated with radioactive Iodine Metaiodobenzylguanidine scintigraphy (mIBG). Sequential echocardiography and CMR indices will be used for heart function and geometry assessment. The investigators will investigate the correlation between the sympathetic tone and the severity of cardiac dysfunction (systolic and diastolic) during the acute phase. Furthermore, the investigators will examine differences of the sympathetic tone effect in association with the localisation of the wall motion abnormality. Stress levels and quality of life will be assessed with respective validated questionnaires. The participants will be followed-up with quarterly clinic reviews for 12 months after the acute event. Baseline measurements will be repeated at the end of the follow-up period. Ethics approval has been obtained from the hospital ethical committee board.

The study results are expected to determine the role of the sympathetic tone on the extend, the severity and the localisation of cardiac dysfunction during the acute phase. They are also expected to demonstrate the role of the sympathetic tone on the long-lasting disorder that persists for months following the acute event.

Read the detailed description

TakoTsubo syndrome is the acute cardiac disorder which mimics an acute coronary syndrome and presents with signs of acute heart failure. It refers to a reversible regional dysfunction of the left ventricular contractility which cannot be attributed to coronary artery disease. Cardiac magnetic resonance is generally recommended as superior to echocardiography as the method to differentiate subjects with myocarditis or subendocardial infarction, but also to detect limited areas of reduced contractility and intracardiac thrombi. Usually, the condition follows an intense stressful event (physical condition or emotional distress). The affected area is usually regional, however cases of focal or global dysfunction of the left ventricle as well as others with right heart involvement have been also described. To date, many potential pathophysiologic processes have been suggested. These are the epicardial spasm, the self-limited acute myocardial infarction, the coronary microcirculatory dysfunction, the left ventricular outflow obstruction and the direct toxicity of the circulating catecholamines. Despite the comprehensive study of this entity during the last three decades, none of the aforementioned mechanisms has been adequately validated. On the other hand, there is increasing evidence regarding the leading role of the sympathetic tone as a main contributor. This has been shown in studies with 123mIBG which demonstrate that during the subacute phase of the syndrome the regional sympathetic enervation appears to be dysfunctional and improves after the recovery of the left ventricular systolic function. On the contrary, the sympathetic tone appears to be increased during the acute phase. There are no data available regarding the sympathetic innervation later than the period of three months from the episode. The MSNA, despite being a useful method to evaluate the sympathetic tone, has been used in TakoTsubo syndrome published series only twice. The available results are conflicting as there was a group of patients whose estimated sympathetic tone, being evaluated with MSNA appeared to be lower during the subacute phase compared with the follow - up period after the systolic recovery of the left ventricle.

Some years ago, despite its initial severity on presentation, the syndrome was regarded as having a benign course. New data, support that Takotsubo syndrome is accompanied by significant morbidity and mortality. Its incidence is estimated at around 2% of the acute coronary syndromes. It is exceptionally high in post-menopausal women. The available data support that short-term mortality ranges around 4-6% and is comparable to the one of the acute coronary syndromes. The disappointing short-term prognosis reflects the increased epidemiological data of in-hospital morbidity.

According to the International Takotsubo Registry, the men to women ratio is 9:1. The two genders share similar clinical and demographic characteristics, however in men, the stressful preceded event is more often physical but in women emotional. Typically, Takotsubo patients compared with others suffering from acute coronary syndromes suffer more frequently from depression and anxious disorder. Of great interest are the results which refer to the long-term morbidity. In detail, there are data for patients one year after the episode of Takotsubo syndrome who despite the left ventricular systolic recovery, express symptoms, functional status and laboratory results compatible with cardiac dysfunction. These findings are accompanied by increased myocardial fibrosis measured in CMR studies and abnormal metabolic function shown in cardiac magnetic spectroscopy. Moreover, it is suggested that the remaining diastolic dysfunction predisposes to worse outcomes. In general, Takotsubo syndrome is exceptionally heterogenous in terms of clinical expression and outcomes.

Aim of this study The main target of this study is to evaluate the sympathetic tone in patients with Takotsubo syndrome and particularly its potential prognostic value regarding its clinical severity on admission but also the left ventricular remodeling (structural and functional) one year after the event. It will be the first registry held in Greece and will try to re-evaluate the value of MSNA as a way to estimate the sympathetic tone in this population. Moreover, the sympathetic tone and sympathetic innervation integrity will be evaluated in patients with other than the typical - apical form of the syndrome according to the recent classification.

Methods This is a prospective, non-interventional observational study which will enroll patients 18-85-year-old, who fulfil the InterTAK diagnostic criteria. The diagnosis will be confirmed with CMR and ECHO which will show the LV systolic recovery. The sympathetic tone will be assessed with heart rate and blood pressure variability, MSNA and 123mIBG. Baseline measurements will be done during a 14-day interval from the acute onset. These will be repeated one year after the event. Signed consent form will be obtained and cases that the symptoms were attributed to myocarditis or subendocardial infarction (CMR result) will be excluded. Patients with severe chronic kidney disease (eGFR < 30 ml/min), severe valvular disease, contraindication to perform any of the aforementioned measurements, chronic atrial fibrillation, permanent pacing, autonomic failure, pregnant or breastfeeding women, psychiatric disease which does not allow adequate co-operation or patients with life expectancy less than a year will not be enrolled. The enrolled cases will be followed up for one year. Data will be collected in a specific form (CRF). These include demographic and somatometric data, past medical history, hemodynamics and sympathetic tone measurements. In detail, the following parameters will be measured. Gender, height, body weight, waist - hip and neck circumference, stress levels (validated questionnaire), tobacco exposure, history of hypertension, diabetes, dyslipidemia, family history of cardiovascular disease. Additionally, the investigators will collect information about the concomitant coronary artery disease, heart failure, paroxysmal atrial fibrillation, chronic kidney disease, peripheral artery disease, sleep apnea, stroke. Moreover, vital signs on admission, ECG findings, ECHO results on admission, cath lab results and laboratory results (estimated renal function, lipids, serum glucose levels, uric acid levels, liver function tests, thyroid function tests, myocardial ischemia biomarkers, natriuretic peptids and inflammatory markers).

Sympathetic tone estimation:

Α. MSNA. After patient's stabilization the test will be performed and the derived data will be the number of bursts per min and the average bursts per 100 beats. The test will be repeated one year after the acute event.

  1. 123 MIBG. Lugol solution will be administered prior to the scan for thyroid protection. After the MIBG administration planar view will be obtained at 15-20 min and this will be repeated 4 hours later together with tomographic scan with γ camera. The measured parameters will be the early and late heart to mediastinum ratio and the washout ratio.
  2. ambulatory heart rate and blood pressure monitoring. Heart rate variability will be analyzed via Kubios software for linear parametric characterization of short-term and long-term heart rate variability. Blood pressure short-term variability will be expressed as SD, wSD, ARV, CV, tame rate of BP variation.

The left ventricle geometry and function will be assessed with:

  1. CMR (pre enrollment and one year after the episode). LV, RV: ESV, EDV, RWMA, atrial volumes, tissue tracking: GLS, RS. T2W-Triple IR/STIR, early and late gadolinium enhancement.
  2. ECHO (acute phase of Takotsubo syndrome, one year after the event). LVEF, E, A, E', A', LA vol, GLS

For data analysis, SPSS 24.0 software will be used. Continuous parametric data will be expressed as mean and SD. For categoric parametric data results will be presented in means of frequency and percentage. Comparisons between categoric parameters will be done with test x2. Comparisons between the mean values for continuous parameters with normal distribution will be done via unpaired student's test. Comparisons between categoric parameters will be done with Mann Whitney U test. Normal distribution will be checked with Kolmogorov-Smirnov test. Correlation analysis will be done via Pearson Phi coefficient or Spearman Rho. Statistically significant will be differences with p value < 0.05. Evaluation of correlations between selected variables and cardiovascular events and mortality will be via Kaplan Maier curves.

Study limitations Sympathetic tone evaluation is not feasible during the hyper-acute phase of the syndrome. Systolic and diastolic function of left ventricle prior to the event will not always be available for comparison. Patients with severe comorbidities will probably not be enrolled in the study as it will be difficult to perform the necessary testing.

Estimated research outcome The present study estimates to include patients who express apart from the typical - apical form of the syndrome, as described in previous diagnostic criteria (revised Mayo) patients with basal, mid-ventricular and focal distribution of the systolic dysfunction of the left ventricle. It is interesting to investigate whether the currently available data regarding the sympathetic tone and the typical form of the syndrome apply for the atypical forms. As for the MSNA method, the investigators estimate to re-evaluate it as a means for sympathetic tone evaluation in takotsubo patients but also its potential prognostic value for the severity of syndrome on presentation and long-term morbidity. Regarding the MIBG scan, the investigators expect to reevaluate its value as an index of topical innervation integrity in patients who fulfil the new diagnostic criteria. Moreover, to test whether the hypokinetic area is related with impaired innervation during the subacute phase and permanent changes as expressed with fibrosis in CMR one year after the event.

Being tested
123 MIBG scintigraphy testing, MSNA, ABPM, ECHO, 24hour ECG
Keywords
sympathetic tone, autonomic nervous system, takotsubo, stress cardiomyopathy, 123MIBG, MSNA, Heart Rate Variability, Blood Pressure Variability
Medical subject headings
Takotsubo Cardiomyopathy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 123 MIBG scintigraphy testingDiagnostic test

    123 MIBG scintigraphy testing in subacute phase and 12 months after the acute episode in a subgroup of patients according to individualized needs.

  • MSNADiagnostic test

    MSNA in subacute phase and 12 months after the acute episode

  • ABPMDiagnostic test

    ABPM in subacute phase and 12 months after the acute episode

  • ECHODiagnostic test

    ECHO in subacute phase and 12 months after the acute episode

  • 24hour ECGDiagnostic test

    24hour ECG in subacute phase and 12 months after the acute episode

  • CMRDiagnostic test

    CMR in 12 months after the acute episode

Study groups in NCT04695587
Study groupRoleWhat they receive
TakoTsuboPatients hospitalized with TakoTsubo syndrome according to the INTERTAK criteria
Receives: Diagnostic Test: 123 MIBG scintigraphy testing; Diagnostic Test: MSNA; Diagnostic Test: ABPM; Diagnostic Test: ECHO; Diagnostic Test: 24hour ECG; Diagnostic Test: CMR

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Degree of systolic dysfunction at baseline regarding the sympathetic tone activity

    Assesses the impact of sympathetic tone activity over the subacute phase of syndrome with regards to the degree of the systolic dysfunction during the acute event.

    Measured: 14 days (subacute phase)

  2. Degree of systolic dysfunction at baseline with regards to the sympathetic tone activity 12 months after the event

    Assesses the impact of sympathetic tone activity over the subacute phase of syndrome as well as one year after the acute episode with regards to the degree of the systolic dysfunction during the acute event.

    Measured: 12 months after the acute event

Secondary outcomes (9)
  1. Degree of diastolic dysfunction at 12 months regarding the sympathetic tone activity at baseline

    Assesses the impact of sympathetic tone activity during the subacute phase of syndrome on the diastolic function one year after the acute episode using ECHO features, as well as retrospective echo data from the patient's history regarding diastolic function prior to the event.

    Measured: 12 months follow up

  2. Degree of diastolic dysfunction at 12 months regarding the sympathetic tone activity at baseline

    Assesses the impact of sympathetic tone activity during the subacute phase of syndrome on the diastolic function one year after the acute episode using CMR features, as well as retrospective echo data from the patient's history regarding diastolic function prior to the event.

    Measured: 12 months follow up

  3. Degree of diastolic dysfunction at 12 months regarding the change of sympathetic tone activity during the follow up period

    Assesses the impact of sympathetic tone activity change during follow up on the diastolic function one year after the acute episode using ECHO features, as well as retrospective echo data from the patient's history regarding diastolic function prior to the event.

    Measured: 12 months follow up

  4. Degree of diastolic dysfunction at 12 months regarding the change of sympathetic tone activity during the follow up period

    Assesses the impact of sympathetic tone activity change during follow up on the diastolic function one year after the acute episode using CMR features, as well as retrospective echo data from the patient's history regarding diastolic function prior to the event.

    Measured: 12 months follow up

  5. Degree of myocardial fibrosis at 12 months regarding the sympathetic tone activity at baseline

    Assesses the impact of sympathetic tone activity over the subacute phase of syndrome with regards to the degree of fibrosis found on CMR one year after the acute episode, if any.

    Measured: 12 months follow up

  6. Degree of myocardial fibrosis at 12 months regarding the change of sympathetic tone activity during the follow up period

    Assesses the impact of sympathetic tone activity change over the follow up period with regards to the degree of fibrosis found on CMR one year after the acute episode, if any.

    Measured: 12 months follow up

  7. Degree of cardiac innervation defect regarding the sympathetic tone activity at baseline

    In the subgroup of patients who will undergo MIBG scan, it assesses the impact of sympathetic tone activity on the cardiac innervation defect derived by the MIBG scan.

    Measured: 14 days (subacute phase)

  8. Cardiac innervation defect at baseline regarding the diastolic function at 12 months

    In the subgroup of patients who will undergo MIBG scan, it assesses the impact of the cardiac innervation defect derived by the MIBG scan during the subacute phase, on the degree of diastolic dysfunction one year after the acute event.

    Measured: 12 months follow up

  9. Remaining cardiac innervation defect at baseline regarding the degree of myocardial fibrosis at 12 months

    In the subgroup of patients who will undergo MIBG scan, it assesses the impact of the cardiac innervation defect derived by the MIBG scan during the subacute phase, on the degree of myocardial fibrosis one year after the acute event.

    Measured: 12 months follow up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Jan 2021
  2. Study start8 Oct 2019
  3. Primary completion7 Oct 2022 (estimated)
  4. Study completion7 Oct 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04695587
Sponsor's protocol ID
1920004531
Acronym
SYMPATAK
Status last verified
Jan 2021
First submitted
23 Dec 2020
Last updated
5 Jan 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Anonymised data may be available for research purposes under the GDPR regulations.

Publications

  • Y-Hassan S. Acute cardiac sympathetic disruption in the pathogenesis of the takotsubo syndrome: a systematic review of the literature to date. Cardiovasc Revasc Med. 2014 Jan;15(1):35-42. doi: 10.1016/j.carrev.2013.09.008. Epub 2013 Oct 18.

    PubMed 24140050
  • Pollick C, Cujec B, Parker S, Tator C. Left ventricular wall motion abnormalities in subarachnoid hemorrhage: an echocardiographic study. J Am Coll Cardiol. 1988 Sep;12(3):600-5. doi: 10.1016/s0735-1097(88)80044-5.

    PubMed 3403818
  • Pavlovitch JH, Rizk-Rabin M, Jaffray P, Hoehn H, Poot M. Characteristics of homogeneously small keratinocytes from newborn rat skin: possible epidermal stem cells. Am J Physiol. 1991 Dec;261(6 Pt 1):C964-72. doi: 10.1152/ajpcell.1991.261.6.C964.

    PubMed 1767823
  • Wittstein IS, Thiemann DR, Lima JA, Baughman KL, Schulman SP, Gerstenblith G, Wu KC, Rade JJ, Bivalacqua TJ, Champion HC. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med. 2005 Feb 10;352(6):539-48. doi: 10.1056/NEJMoa043046.

    PubMed 15703419
  • Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, Cammann VL, Crea F, Galiuto L, Desmet W, Yoshida T, Manfredini R, Eitel I, Kosuge M, Nef HM, Deshmukh A, Lerman A, Bossone E, Citro R, Ueyama T, Corrado D, Kurisu S, Ruschitzka F, Winchester D, Lyon AR, Omerovic E, Bax JJ, Meimoun P, Tarantini G, Rihal C, Y-Hassan S, Migliore F, Horowitz JD, Shimokawa H, Luscher TF, Templin C. International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management. Eur Heart J. 2018 Jun 7;39(22):2047-2062. doi: 10.1093/eurheartj/ehy077.

    PubMed 29850820
  • Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, Cammann VL, Crea F, Galiuto L, Desmet W, Yoshida T, Manfredini R, Eitel I, Kosuge M, Nef HM, Deshmukh A, Lerman A, Bossone E, Citro R, Ueyama T, Corrado D, Kurisu S, Ruschitzka F, Winchester D, Lyon AR, Omerovic E, Bax JJ, Meimoun P, Tarantini G, Rihal C, Y-Hassan S, Migliore F, Horowitz JD, Shimokawa H, Luscher TF, Templin C. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. Eur Heart J. 2018 Jun 7;39(22):2032-2046. doi: 10.1093/eurheartj/ehy076.

    PubMed 29850871
  • Sharkey SW, Maron BJ. Epidemiology and clinical profile of Takotsubo cardiomyopathy. Circ J. 2014;78(9):2119-28. doi: 10.1253/circj.cj-14-0770. Epub 2014 Aug 5.

    PubMed 25099475
  • Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, Cammann VL, Sarcon A, Geyer V, Neumann CA, Seifert B, Hellermann J, Schwyzer M, Eisenhardt K, Jenewein J, Franke J, Katus HA, Burgdorf C, Schunkert H, Moeller C, Thiele H, Bauersachs J, Tschope C, Schultheiss HP, Laney CA, Rajan L, Michels G, Pfister R, Ukena C, Bohm M, Erbel R, Cuneo A, Kuck KH, Jacobshagen C, Hasenfuss G, Karakas M, Koenig W, Rottbauer W, Said SM, Braun-Dullaeus RC, Cuculi F, Banning A, Fischer TA, Vasankari T, Airaksinen KE, Fijalkowski M, Rynkiewicz A, Pawlak M, Opolski G, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Crea F, Dichtl W, Franz WM, Empen K, Felix SB, Delmas C, Lairez O, Erne P, Bax JJ, Ford I, Ruschitzka F, Prasad A, Luscher TF. Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med. 2015 Sep 3;373(10):929-38. doi: 10.1056/NEJMoa1406761.

    PubMed 26332547
  • Stiermaier T, Thiele H, Eitel I. Long-term excess mortality in Takotsubo syndrome: is it justified to charge Takotsubo for the excess long-term mortality?: Reply. Eur J Heart Fail. 2016 Jul;18(7):879. doi: 10.1002/ejhf.573. Epub 2016 May 30. No abstract available.

    PubMed 27241281
  • Scally C, Rudd A, Mezincescu A, Wilson H, Srivanasan J, Horgan G, Broadhurst P, Newby DE, Henning A, Dawson DK. Persistent Long-Term Structural, Functional, and Metabolic Changes After Stress-Induced (Takotsubo) Cardiomyopathy. Circulation. 2018 Mar 6;137(10):1039-1048. doi: 10.1161/CIRCULATIONAHA.117.031841. Epub 2017 Nov 11.

    PubMed 29128863
  • Nowak R, Fijalkowska M, Gilis-Malinowska N, Jaguszewski M, Galaska R, Rojek A, Narkiewicz K, Gruchala M, Fijalkowski M. Left ventricular function after takotsubo is not fully recovered in long-term follow-up: A speckle tracking echocardiography study. Cardiol J. 2017;24(1):57-64. doi: 10.5603/CJ.a2017.0001. Epub 2017 Jan 10.

    PubMed 28070881
  • Bratis K. Cardiac Magnetic Resonance in Takotsubo Syndrome. Eur Cardiol. 2017 Aug;12(1):58-62. doi: 10.15420/ecr.2017:7:2.

    PubMed 30416553
  • Nakajima K, Scholte AJHA, Nakata T, Dimitriu-Leen AC, Chikamori T, Vitola JV, Yoshinaga K. Cardiac sympathetic nervous system imaging with 123I-meta-iodobenzylguanidine: Perspectives from Japan and Europe. J Nucl Cardiol. 2017 Jun;24(3):952-960. doi: 10.1007/s12350-017-0818-y. Epub 2017 Mar 13.

    PubMed 28290098
  • Pina IL, Carson P, Lindenfeld J, Archambault WT, Jacobson AF. Persistence of 123I-mIBG Prognostic Capability in Relation to Medical Therapy in Heart Failure (from the ADMIRE-HF Trial). Am J Cardiol. 2017 Feb 1;119(3):434-439. doi: 10.1016/j.amjcard.2016.10.024. Epub 2016 Oct 31.

    PubMed 27912890
  • Akashi YJ, Nakazawa K, Sakakibara M, Miyake F, Musha H, Sasaka K. 123I-MIBG myocardial scintigraphy in patients with "takotsubo" cardiomyopathy. J Nucl Med. 2004 Jul;45(7):1121-7.

    PubMed 15235057

Questions about this trial

What is this clinical trial studying?

An observational study of Takotsubo Cardiomyopathy, run by Hippocration General Hospital at 1 site in Greece.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 5 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Konstantinos P Tsioufis, Professor (21320880000 ext. 8099, ktsioufis@hippocratio.gr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Degree of systolic dysfunction at baseline regarding the sympathetic tone activity (time frame: 14 days (subacute phase)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04695587, which also lists 19 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jan 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in